LifeArc plays key role in discovery of new Alzheimer’s treatment
LifeArc played an important part in the discovery of lecanemab, an experimental drug that has shown some benefits for people with early Alzheimer’s disease.
We had a fantastic time at #RAREfest22 with @camraredisease.
It was great to see the #LifeScience and rare diseas… https://t.co/nb4o0FuOSh
LifeArc contributes to organic chemistry breakthrough
The findings reveal that seemingly impossible chemical reactions can be driven through a phenomenon called quantum tunnelling.
AbbVie acquires LifeArc portfolio company DJS Antibodies
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS
LifeArc’s new fund to advance gene-based medicines for genetic diseases
Researchers can now apply for funding to progress exciting gene therapy research.
New toolkit launched to help repurposed medicines reach patients
The toolkit helps researchers, charities and others navigate the opportunities and challenges of repurposing medicines.
LifeArc scientist awarded prestigious industrial fellowship
LifeArc scientist Finbar Gaffey awarded a coveted industrial fellowship from the Royal Commission for the Exhibition of 1851.
Aisling Burnand CBE, 1964-2022
It is with deep sadness that we share the news that Aisling Burnand CBE passed away on Monday 19 September 2022.
Separate science from politics: save the UK’s science sector
LifeArc's Chief Scientific Officer calls for UK science to continue to be a contributor to the Horizon Europe programme.
Seven questions about LifeArc’s 2030 ambitions
Melanie Lee talks about LifeArc’s commitment to patients, and explains why we should all care about science translation.